Mr. Mainville is the President and Founder of LUMA Capital and LUMA Life, previously serving as Executive Vice President of Cardiome Pharma Corp., and President and Chief Executive Officer of Neopharm Labs Inc. and LAB Research Inc. He brings considerable experience throughout his career in which he has served in senior corporate, and director roles for a number of public and private companies in the biotechnology and pharmaceutical industries. In particular, Mr. Mainville has led more than 30 mergers and acquisitions, as well as served as Chair of the Board of Alethia BioTherapeutics, Bioaxone Therapeutics, and Powertech Corporation as well as Chair of the Audit Committee for a number of Boards, including that of Acerus Pharma, Enobia Pharma, and Cyplasin Biomedical. He served as Vice-Chairman of BioteCanada, and also teaches corporate governance and mergers and acquisitions courses at McGill University in Montreal, Quebec. Prior to his career in the life science industry, he was a Partner at KPMG.
Claude Piche, PhD
Co-Creator and CEO, Locemia Solutions
As Co-Founder, President and CEO of Locemia Solutions, Dr. Piché led the company from start up through to completion of phase III clinical studies, ultimately resulting in the sale of its glucagon nasal powder technology to Eli Lilly in October 2015. He has over 25 years of experience in developing and commercializing pharmaceuticals, vaccines, and diagnostics, including more than 15 years where he focused on diabetes therapeutics and hypoglycemia-related technologies. He has worked at large companies such as Merck, as well as start-up biopharmaceutical companies where he had roles in research, regulatory affairs, marketing, and operations.
President and CEO, CDRD (Centre for Drug Research and Development)
Gordon McCauley was appointed President and CEO of CDRD in 2017 after serving on the Board for four years. Mr. McCauley is an accomplished life science investor and executive. He has served as President & CEO of Viable Healthworks Corp., a national healthcare service business; President and CEO of Allon Therapeutics Inc., a neuroscience biotechnology company that developed novel therapeutics from pre-clinical to global phase 3 studies before being sold; and Co-Founder and Partner of NDI Capital, an institutionally-backed life-science investment fund. Mr. McCauley has also been a senior executive of several successful health care enterprises and a senior advisor to several prominent Canadian political leaders.
Mr. McCauley has been a Director of a number of both private and publicly traded companies. Currently Mr. McCauley is a Director of CDRD (and a number of its portfolio and subsidiary companies), BIOTECanada, Canada’s national biotech industry organization, and Chairman of the Board, CGen, Canada’s national genomics enterprise. Until recently, he was also a Director of LifeSciences British Columbia and served as its Chair from 2012 – 2015. In 2008 Mr. McCauley was the first Canadian appointed to the Board of The Biotechnology Industry Organization (BIO) in Washington D.C., where he served in leadership positions until 2013. He is Past Chair of Acetech, and was a founding Director of the Toronto Rehabilitation Institute and Past Chair of the Toronto Rehab Foundation.
Parimal Nathwani, MSc, MBA
Vice President, Life Sciences, MaRS Innovation
Parimal Nathwani has over 15 years of experience in various aspects of the biotechnology industry, including corporate finance, business development, transactions, intellectual property management, technology development and operations. He has been actively involved in forming and managing start-ups, preparing and executing on business plans, raising early-stage capital, and in- and out-licensing activities.
Before joining MaRS Innovation, Parimal was a healthcare analyst with a boutique investment bank, where he conducted equity research on publicly-traded biotechnology companies in Canada and the U.S. He has also led commercialization activities out of BC Women’s and Children’s Hospital as part of his role at the University of British Columbia’s Industry Liaison Office, and was a research scientist at a start-up biotechnology company involved in drug discovery targeting ABC Transporters.
Parimal received his MBA from Simon Fraser University and his M.Sc. from the University of British Columbia. He currently sits on the board of ScarX Therapeutics (Chairman), Zucara Therapeutics, and is an observer on the boards of Encycle Therapeutics and Vasomune Therapeutics.
Michael Midmer, MSc, MBA
Chief Executive Officer, Zucara Therapeutics
Michael has over 15 years of experience in the life science industry, fund management and corporate finance. Michael was formerly the Director of the Genomic Applications Partnership Program (GAPP) at Genome Canada. The GAPP program funded partnerships between industry and academia including companies such as Xagenic, Vasomune, Assurex and Roche.
Before joining Genome Canada, Michael was a Director at Rosetta Capital, an international venture capital firm, where he managed a portfolio of over 30 companies in North America and Europe including company exits such as Enobia, Cytochroma, Ambit and Resonant. Michael was also Business Development Manager at KS Biomedix and was Investor Relations Manager at Cardiome Pharma. In addition, Michael has been a board member for several companies and was the Chair of a not-for-profit board.
Michael has an MSc in molecular biology from the University of Toronto (Canada) and an MBA from Imperial College Business School (UK). He has also completed the Canadian Securities Course.